Newman, Erik
Thompson, Wesley K.
Bartsch, Hauke
Hagler, Donald J. Jr.
Chen, Chi-Hua
Brown, Timothy T.
Kuperman, Joshua M.
McCabe, Connor
Chung, Yoonho
Libiger, Ondrej
Akshoomoff, Natacha
Bloss, Cinnamon S.
Casey, B. J.
Chang, Linda
Ernst, Thomas M.
Frazier, Jean A.
Gruen, Jeffrey R.
Kennedy, David N.
Murray, Sarah S.
Sowell, Elizabeth R.
Schork, Nicholas
Kenet, Tal
Kaufmann, Walter E.
Mostofsky, Stewart
Amaral, David G.
Dale, Anders M.
Jernigan, Terry L.
Funding for this research was provided by:
National Institute on Drug Abuse (RC2 DA029475)
National Institute of Child Health and Human Development (R01 HD061414)
National Institute of General Medical Sciences (R01 GM104400)
Article History
Received: 30 March 2015
Accepted: 7 July 2015
First Online: 17 July 2015
Compliance with ethical standards
:
: Jean A. Frazier has received research support from GlaxoSmithKline, Pfizer, Inc., Neuren, Roche, and Seaside Therapeutics, NICHD, NIMH, NINDS and has served on a Data Safety Monitoring Board for Forest Pharmaceuticals. Anders M. Dale is a founder of and holds equity interest in CorTechs Labs, La Jolla, CA and serves on its scientific advisory board. The terms of this arrangement have been reviewed and approved by UC San Diego, in accordance with its conflict of interest policies. All other authors reported no biomedical financial interests or potential conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.